India's Penicillin G Manufacturing Revival

• 08 Mar 2024

Recently, India has decided to revive Penicillin G production after 3 decades, aiming for self-reliance in pharmaceuticals.

Key Points

• Reason for Halt: Penicillin G production ceased due to influx of cheaper Chinese alternatives. Indian manufacturers faced viability challenges.
• Impact on Industry: Subsidy-driven imports led to decline in Indian Active Pharmaceutical Ingredient (API) manufacturing. PLI scheme launched to boost domestic production.
• Challenges Faced: Restarting production entails high initial costs and competition with established Chinese suppliers.
• Impact of PLI Scheme: PLI scheme results in reduced API imports, fostering self-reliance.
• Scheme Details: PLI scheme offers incentives for fermentation-based bulk drugs and chemically synthesized drugs.